Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor

Abstract The current paradigm of cancer medicine focuses on patient‐ and/or cancer‐specific treatments, which has led to continuous progress in the development of patient representatives (e.g., organoids) and cancer‐targeting carriers for drug screening. As breakthrough concepts, i) living cancer ti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hyo‐Jin Yoon, Young Shin Chung, Yong Jae Lee, Seung Eun Yu, Sewoom Baek, Hye‐Seon Kim, Sang Wun Kim, Jung‐Yun Lee, Sunghoon Kim, Hak‐Joon Sung
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	cancer cell‐derived nanovesicles ovarian cancer patient‐specific treatments self‐homing nano‐targeting tissueoid Science Q
Acceso en línea:	https://doaj.org/article/e8e6201eb435440cbaab6765c1b052e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e8e6201eb435440cbaab6765c1b052e1
record_format	dspace
spelling	oai:doaj.org-article:e8e6201eb435440cbaab6765c1b052e12021-11-17T08:40:31ZCancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor2198-384410.1002/advs.202102640https://doaj.org/article/e8e6201eb435440cbaab6765c1b052e12021-11-01T00:00:00Zhttps://doi.org/10.1002/advs.202102640https://doaj.org/toc/2198-3844Abstract The current paradigm of cancer medicine focuses on patient‐ and/or cancer‐specific treatments, which has led to continuous progress in the development of patient representatives (e.g., organoids) and cancer‐targeting carriers for drug screening. As breakthrough concepts, i) living cancer tissues convey intact profiles of patient‐specific microenvironmental signatures. ii) The growth mechanisms of cancer mass with intense cell‐cell interactions can be harnessed to develop self‐homing nano‐targeting by using cancer cell‐derived nanovesicles (CaNVs). Hence, a tissueoid model of ovarian cancer (OC) is developed by culturing OC patient tissues in a 3D gel chip, whose microchannel networks enable perfusion to maintain tissue viability. A novel model of systemic cancer responses is approached by xenografting OC tissueoids into ischaemic hindlimbs in nude mice. CaNVs are produced to carry general chemotherapeutics or new drugs under pre/clinical studies that target the BRCA mutation or energy metabolism, thereby increasing the test scope. This pioneer study cross‐validates drug responses from the OC clinic, tissueoid, and animal model by demonstrating the alignment of results in drug type‐specific efficiency, BRCA mutation‐dependent drug efficiency, and metabolism inhibition‐based anti‐cancer effects. Hence, this study provides a directional foundation to accelerate the discovery of patient‐specific drugs with CaNV application towards future precision medicine.Hyo‐Jin YoonYoung Shin ChungYong Jae LeeSeung Eun YuSewoom BaekHye‐Seon KimSang Wun KimJung‐Yun LeeSunghoon KimHak‐Joon SungWileyarticlecancer cell‐derived nanovesiclesovarian cancerpatient‐specific treatmentsself‐homing nano‐targetingtissueoidScienceQENAdvanced Science, Vol 8, Iss 22, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cancer cell‐derived nanovesicles ovarian cancer patient‐specific treatments self‐homing nano‐targeting tissueoid Science Q
spellingShingle	cancer cell‐derived nanovesicles ovarian cancer patient‐specific treatments self‐homing nano‐targeting tissueoid Science Q Hyo‐Jin Yoon Young Shin Chung Yong Jae Lee Seung Eun Yu Sewoom Baek Hye‐Seon Kim Sang Wun Kim Jung‐Yun Lee Sunghoon Kim Hak‐Joon Sung Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
description	Abstract The current paradigm of cancer medicine focuses on patient‐ and/or cancer‐specific treatments, which has led to continuous progress in the development of patient representatives (e.g., organoids) and cancer‐targeting carriers for drug screening. As breakthrough concepts, i) living cancer tissues convey intact profiles of patient‐specific microenvironmental signatures. ii) The growth mechanisms of cancer mass with intense cell‐cell interactions can be harnessed to develop self‐homing nano‐targeting by using cancer cell‐derived nanovesicles (CaNVs). Hence, a tissueoid model of ovarian cancer (OC) is developed by culturing OC patient tissues in a 3D gel chip, whose microchannel networks enable perfusion to maintain tissue viability. A novel model of systemic cancer responses is approached by xenografting OC tissueoids into ischaemic hindlimbs in nude mice. CaNVs are produced to carry general chemotherapeutics or new drugs under pre/clinical studies that target the BRCA mutation or energy metabolism, thereby increasing the test scope. This pioneer study cross‐validates drug responses from the OC clinic, tissueoid, and animal model by demonstrating the alignment of results in drug type‐specific efficiency, BRCA mutation‐dependent drug efficiency, and metabolism inhibition‐based anti‐cancer effects. Hence, this study provides a directional foundation to accelerate the discovery of patient‐specific drugs with CaNV application towards future precision medicine.
format	article
author	Hyo‐Jin Yoon Young Shin Chung Yong Jae Lee Seung Eun Yu Sewoom Baek Hye‐Seon Kim Sang Wun Kim Jung‐Yun Lee Sunghoon Kim Hak‐Joon Sung
author_facet	Hyo‐Jin Yoon Young Shin Chung Yong Jae Lee Seung Eun Yu Sewoom Baek Hye‐Seon Kim Sang Wun Kim Jung‐Yun Lee Sunghoon Kim Hak‐Joon Sung
author_sort	Hyo‐Jin Yoon
title	Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
title_short	Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
title_full	Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
title_fullStr	Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
title_full_unstemmed	Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor
title_sort	cancer patient tissueoid with self‐homing nano‐targeting of metabolic inhibitor
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/e8e6201eb435440cbaab6765c1b052e1
work_keys_str_mv	AT hyojinyoon cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT youngshinchung cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT yongjaelee cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT seungeunyu cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT sewoombaek cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT hyeseonkim cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT sangwunkim cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT jungyunlee cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT sunghoonkim cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor AT hakjoonsung cancerpatienttissueoidwithselfhomingnanotargetingofmetabolicinhibitor
_version_	1718425706628644864

Cancer Patient Tissueoid with Self‐Homing Nano‐Targeting of Metabolic Inhibitor

Ejemplares similares